Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
318
days
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
Authors
Sha Liu; Junjun Lu; Zhaojie Lyu; Zhengmao Lu; Yunmei Liu; Ruiying Zhang; Wentao Xu; Guoping Sun; Yingying Du; Lei HuangShow moreShow less
Affiliations
1. The First Affiliated Hospital of Anhui Medical University; 2. Peking University Shenzhen Hospital; 3. The First Affiliated Hospital of Naval Medical University; 4. Shanghai University; 5. Guangzhou University of Chinese Medicine; 6. Anhui Medical University; 7. The First Affiliated Hospital of Naval Medical University/Changhai Hospital, Naval Medical UniversityShow moreShow less
155
days
Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
Authors
Xiaoyue Ren; Lijie Zhang; Linli Zhou; Shuqi ZhaoShow moreShow less
Affiliations
1. Shaanxi Provincial People’s Hospital; 2. Changde First Hospital of Traditional ChineseShow moreShow less
53
days
Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States
Authors
Xiaohan Hu; Amin Haiderali; Yezhou Sun; Wilbur PanShow moreShow less
Affiliations
1. Value & Implementation Outcomes Research Oncology; 2. BARDS RWE Capabilities and Analytics; 3. Global Clinical DevelopmentShow moreShow less
145
days
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
Authors
Zhiwei Zheng; Lisheng Huang; Yuling Zhang; Huide Zhu; Ling FangShow moreShow less
Affiliations
1. Cancer Hospital of Shantou University Medical College; 2. Shantou University Medical CollegeShow moreShow less
82
days
Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan
Authors
Hiroe Suzuki-Chiba; Atsushi MiyawakiShow moreShow less
Affiliations
1. The University of Tokyo; 2. University of TsukubaShow moreShow less
182
days
Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer
Authors
Alfredo Tartarone; Raffaele Conca; Alessandra Perrone; Rosa LeroseShow moreShow less
Affiliations
1. IRCCS-CROB Referral Cancer Center of BasilicataShow moreShow less
FAQ
How long does Immunotherapy take to review a manuscript?
As of 2026-11-19, CrushSCI has 19 complete review records for Immunotherapy. The fastest paper went from submission to acceptance in 43 days (Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiency, received 2026-06-04, accepted 2026-07-17); the slowest took 318 days. The average is 145.2 days and the median is 137 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
